Serum Interleukin-6 Concentration Associated with Response to Therapy for Chronic Hepatitis C Patients

Amal Ahmed Mohamed, Naglaa El-Toukhy, Ehab M Reyad, Noha Abdel- Rahman Eldesoky


Introduction: Egypt has the highest prevalence of (HCV) in the world. Interleukin 6 is a pleiotropic cytokine that increased in chronic hepatitis C patients. IL-6 was suggested by several studies to play a major role in response to HCV therapy

Aim: The aim of this work was to assess the possible role of IL-6 on response status of patients with HCV during treatment. Also we try to use IL-6 as a predictive factor for response in patients with chronic HCV.

Patients and Methods: Serum concentrations of Interleukin 6 (IL6) was measured before and after treatment using a commercially available Quantikine enzyme linked immunosorbent assay in fifty seven patients with chronic hepatitis C treated with sofosbuvir and simeprevir for 3 months.

Results: The Mean values of IL6 level in responders and non-responders were 272.96 and 230.5 pg/mL respectively. IL-6 levels decrease significantly after treatment in SVR. the best cut-off point for IL6 was 233 pg/mL with a sensitivity of 70%, a specificity of 75% and a positive predictive value of 97.2%, negative predictive value of 16.7%.

Conclusion: Virological response during HCV therapy was associated with decrease in IL-6 level.


Hepatitis C virus; SVR; Interleukin-6; HCV Therapy

Full Text: PDF HTML


  • There are currently no refbacks.

Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.